The FDA is set to approve nearly 5,000 medical devices this year, including a massive surge in radiology AI/software and rapid-fire innovation in cardiovascular and robotics service lines. As a result, sourcing, inventory and contracting for these technologies will be significantly challenged. This presentation addresses these critical obstacles—shifting from capital to digitization and subscription, rapid adoption of AI requiring integration costs, and iterative innovation outpacing payer policies—and the changes needed to adapt and iterate along with them. At the center of those changes are key partnerships across clinical, operational and financial leaders. Join this panel as they engage in meaningful discussion in navigating this innovative pathway at scale.
